Director Sells 50,000 Shares of Digital Health Platform Stock for $1.9 Million, According to Recent SEC Filing
Key Points
50,000 Class A shares were sold on April 1, 2026, with a transaction value of ~$1.92 million based on a weighted average price of $38.46 per share.
This disposition represented 100.00% of Mecklenburg's direct Class A Common Stock holdings at the time, reducing his direct Class A position to zero.
All shares sold were held directly and originated from the conversion of derivative securities; no indirect entities participated in this transaction.
- 10 stocks we like better than Hinge Health ›
On April 1, 2026, Gabriel M.I. Mecklenburg, Director at Hinge Health (NYSE:HNGE), executed the sale of 50,000 Class A Common Stock shares for a total consideration of approximately $1.92 million, according to the SEC Form 4 filing.
Transaction summary
| Metric | Value |
|---|---|
| Shares sold (direct) | 50,000 |
| Transaction value | $1.9 million |
| Post-transaction shares (direct) | 0 |
| Post-transaction value (direct ownership) | ~$0 |
Transaction value based on SEC Form 4 weighted average purchase price ($38.46); post-transaction value based on April 1, 2026 market close ($38.49).
Key questions
- What is the derivative context for this sale?
The 50,000 Class A shares sold originated from the conversion of derivative securities, with the conversion occurring immediately prior to sale, aligning with common liquidity practices among equity holders with substantial vested options. - How does this transaction affect Mecklenburg's ownership in Hinge Health?
The sale reduced Mecklenburg's direct Class A Common Stock holdings to zero, but he continues to hold 3,268,813 Class B Common Stock shares (direct and indirect), which are fully convertible to Class A shares, supporting ongoing beneficial ownership. - Is this transaction part of a routine plan or discretionary action?
This transaction is part of a Rule 10b5-1 trading plan adopted by Mecklenburg on Dec. 1, 2025. - What is the context for transaction pricing relative to market levels?
The weighted average sale price of around $38.46 per share was in line with the April 1, 2026 market close of $38.49, suggesting no price concession for liquidity and reflecting normal market execution for volume at this scale.
Company overview
| Metric | Value |
|---|---|
| Price (as of market close 2026-04-01) | $38.46 |
| Market capitalization | $3.07 billion |
| Revenue (TTM) | $587.86 million |
| Net income (TTM) | -$528.26 million |
* 1-year performance is calculated using April 1st, 2026 as the reference date.
Company snapshot
- Delivers digital healthcare solutions for musculoskeletal conditions, including joint and muscle health, acute injury, chronic pain, and post-surgical rehabilitation.
- Operates a software-driven platform that provides care management and support services for musculoskeletal conditions.
Hinge Health, Inc. is a healthcare technology company specializing in digital musculoskeletal care, leveraging a scalable software platform to address complex joint and muscle conditions.
What this transaction means for investors
Hinge Health stock has been on a rollercoaster of late. Over the last 12 months, shares soared by as much as 80%, before pulling back. Overall, shares have advanced by 23% over the last year. However, they have declined by 15% year to date, driven by broader market weakness.
The company, which operates in the health technology industry, reported solid fourth-quarter results in February 2026. Revenue increased by 46% year-over-year to $171 million, while free cash flow was $62 million, a 65% year-over-year increase. As a growth stock, Hinge remains focused on expanding its customer base and revenue. Total customers increased 25% to more than 2,800.
Turning to valuation, Hinge is looking more attractive, as its price-to-sales (P/S) ratio declines as revenue grows. For example, Hinge’s current P/S ratio stands at 5.4x, down from more than 10x in September 2025.
For growth-oriented investors interested in the health technology sector, Hinge Health is a stock to keep an eye on.
Should you buy stock in Hinge Health right now?
Before you buy stock in Hinge Health, consider this:
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Hinge Health wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years.
Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you’d have $532,066!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you’d have $1,087,496!*
Now, it’s worth noting Stock Advisor’s total average return is 926% — a market-crushing outperformance compared to 185% for the S&P 500. Don't miss the latest top 10 list, available with Stock Advisor, and join an investing community built by individual investors for individual investors.
See the 10 stocks »
*Stock Advisor returns as of April 6, 2026.
Jake Lerch has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.
Recommended Articles
